There is a similar risk of nonfatal venous thromboembolism (VTE) between transdermal and oral contraceptives
- PDF / 136,638 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 77 Downloads / 139 Views
1
■ There is a similar risk of nonfatal venous thromboembolism (VTE) between transdermal and oral contraceptives (OCs), according to further results from a nested case-control study.* Data were obtained from the PharMetrics database for women, aged 15–44 years, who were current users of an ethinylestradiol/norelgestromin transdermal patch or an OC combining norgestimate with ethinylestradiol 35µg.** A total of 56 cases of idiopathic VTE, not included in the previous study, were identified and matched with 212 controls; the OR for VTE, comparing transdermal patch users with OC users, was 1.1 (95% CI 0.6, 2.1). Combining this data with that of the original study resulted in 124 cases and 478 matched controls; the combined OR for VTE among transdermal patch users, compared with OC users, was 1.0 (0.7, 1.5). * See Reactions 1101 p3; 800992600 ** This study was funded by Johnson & Johnson Pharmaceutical Research and Development. Jick S, et al. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 micrograms of ethyl estradiol. 801092030 Contraception 76: 4-7, No. 1, Jul 2007
0114-9954/10/1167-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 1 Sep 2007 No. 1167
Data Loading...
